JPRN-UMIN000015453已完成未知
A multicenter comparison study between [11C]PBB3 PET and histopathology - PBB3 4th protocol(Multicenter)
ational Institute of Radiological Sciences0 个研究点目标入组 480 人开始时间: 2014年10月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 480
研究概览
简要总结
[11C]PBB3 PET showed that tau pathology was observed in the area of high ligand accumulation. The results of this study were presented at national and international conferences, and a paper is in preparation.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •healthy volunteer 1. Subjects with organic brain complications/disorders (including a history of symptomatic cerebral infarction, Parkinson's disease and similar conditions). 2. Patients with substance-related disorders (including drug abuse). For the acceptable range of allowable drugs. 3. Subjects with severe physical complications/disorders or a history of such conditions and who are considered to be inappropriate for participation by the aforementioned doctors with responsibilities in this study. 4. Subjects with a pacemaker or other metallic medical device in the body (brain clip, bolts, etc.). 5. Subjects with tattoos. Subjects with claustrophobia. 6. Pregnant, possibly pregnant or lactating women. 7. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 6 months prior to the start of this study. 8. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study. Patients with probably tau-mediated neuropsychiatric disorders Patients with ante-mortem consent for autopsy Details of exclusion criteria are determined separately in each center.
研究者
相似试验
已完成
不适用
Mapping of brain tau deposition in tauopathy by PET with [11C]PBB3Healthy volunteers 20 years of age or older at the time of obtaining consent Patients with mild cognitive impairment (MCI) 20 years of age or older at the time of obtaining consent Patients with Alzheimer's disease (AD) 20 years of age or older at the time of obtaining consent Patients with corticobasal degeneration (CBD) 20 years of age or older at the time of obtaining consent Patients with progressive supranuclear palsy (PSP) 20 years of age or older at the time of obtaining consent Patients with frontotemporal dementia (FTD) 20 years of age or older at the time of obtaining consent Patients with familial Parkinson's disease with the LRRK2 genetic mutation (PARK8)JPRN-UMIN000009863ational Institute of Radiological Sciences124
已完成
不适用
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal DementiaPrimary Progressive AphasiaBehavioral Variant of Frontotemporal DementiaFrontotemporal Dementia, Behavioral VariantNCT02736695Mayo Clinic81
招募中
不适用
Clinical Study of [18F] PM-PBB3 PET Imaging of Tau Protein in Neurodegenerative DiseasesNeurodegenerative DiseasesNCT06344845Peking Union Medical College Hospital80
招募中
2 期
The Influence of [18F]PMPBB3 and [18F]THK5351 PET Distribution Patterns on Post-stroke Cognitive ImpairmentPost-stroke Cognitive ImpairmentNeuroinflammationNCT04318626Chang Gung Memorial Hospital80
已完成
4 期
Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's DiseaseAlzheimer's DiseaseNCT00800709Shanghai Mental Health Center26